AbCellera Biologics (ABCL) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategy

• Focuses on antibody discovery and development, leveraging advanced technology to address challenging biotargets and build a robust platform over 12 years.

• Evolved from fee-for-service and royalty-based partnerships to co-development and wholly owned programs, increasing value capture.

• Emphasizes internal pipeline growth, with two programs entering IND-enabling studies and a broader portfolio in development.

• Strategic partnerships with major pharma companies have shaped technology investments and validated capabilities.

Key partnerships and collaborations

• Longstanding collaborations with Gilead, Regeneron, AbbVie, Incyte, Biogen, and Eli Lilly, with recent expansions for additional targets.

• Eli Lilly partnership led to successful COVID-19 antibody therapeutics and expanded to cover more targets.

• New collaborations in T-cell engager space and manufacturing, including Biogen and ongoing discussions with other pharma groups.

• Manufacturing capabilities now include CMC and GMP, supporting both internal and partner programs.

Internal pipeline and product development

• Shifted focus toward internally developed assets, progressing from royalty and equity models to wholly owned programs.

• Pipeline includes 19-20 programs, with ABCL-635 and ABCL-575 set to enter the clinic next year.

• ABCL-575 targets OX40 ligand for atopic dermatitis, aiming for differentiation through dosing frequency and seeking a partner for later-stage trials.

• ABCL-635 is a first-in-class antibody for a metabolic/endocrine indication, with a potential $2B market and expected target disclosure in Q2 2025.